Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma

被引：3
|
作者：
Dong, Renshun [1 ,2 ,3 ]
Wang, Tianci [1 ,2 ,3 ]
Dong, Wei [1 ,2 ,3 ,4 ,5 ,6 ]
Zhu, He [1 ,2 ,3 ,4 ,5 ,6 ]
Liu, Qiumeng [1 ,2 ,3 ,4 ,5 ]
Liang, Huifang [1 ,2 ,3 ,4 ,5 ,6 ]
Chen, Xiaoping [1 ,2 ,3 ,4 ,5 ,6 ]
Zhang, Bixiang [1 ,2 ,3 ,4 ,5 ,6 ]
Zhang, Xuewu [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Hepat Surg Ctr, Wuhan 430030, Hubei, Peoples R China
[2] Hubei Key Lab Hepatopancreato Biliary Dis, Wuhan 430030, Hubei, Peoples R China
[3] Hubei Prov Clin Med Res Ctr Hepat Surg, Wuhan 430030, Hubei, Peoples R China
[4] Minist Educ, Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China
[5] Chinese Acad Med Sci, NHC Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China
[6] Chinese Acad Med Sci, Key Lab Organ Transplantat, Wuhan 430030, Hubei, Peoples R China
来源：
BIOMEDICINE & PHARMACOTHERAPY | 2024年 / 173卷
基金：
中国国家自然科学基金;
关键词：
PTPRE inhibitor; Hepatocellular carcinoma; Sorafenib; Organoid; OPEN-LABEL; PLUS; ATEZOLIZUMAB; BEVACIZUMAB; METABOLISM; MYC;
D O I：
10.1016/j.biopha.2024.116366
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Hepatocellular carcinoma (HCC) has a poor prognosis, and the efficacy of current therapeutic strategies is extremely limited in advanced diseases. Our previous study reported that protein tyrosine phosphatase receptor epsilon (PTPRE) is a promoting factor in HCC progression. In this study, our objective was to evaluate the treatment effect of PTPRE inhibitors in different HCC preclinical models. Our results indicated that the PTPRE inhibitory compound 63 (Cpd-63) inhibited tumor cell proliferation, migration, and HCC organoid growth. Mechanism research revealed that Cpd-63 could inhibit the expression of MYC and MYC targets by inhibiting the activation of SRC. Additionally, we found that Cpd-63 could improve the response of sorafenib in HCC cells. In conclusion, we demonstrated that the PTPRE inhibitors represented a potential therapeutic agent for HCC management.
引用
收藏
页数：11
相关论文
共 50 条
  • [41] Inhibition of hepatocellular carcinoma progression by methotrexate-modified pH-sensitive sorafenib and schisandrin B micelles
    Yan, Yu-hui
    Kong, Liang
    Lu, Ying-bo
    Li, Si-yang
    Yan, Ai-wen
    Song, Yue-wen
    Huang, Zi-han
    Zhu, Hao-nan
    BIOMEDICAL MATERIALS, 2025, 20 (01)
  • [42] A polymeric nanoformulation improves the bioavailability and efficacy of sorafenib for hepatocellular carcinoma therapy
    Chen, Yang
    Li, Jia-Xian
    Shu, Na
    Zheng, Sui-Juan
    Ma, Min
    Zhao, Zhi-Bin
    Cao, Zhi-Ting
    Zhou, Qi
    Du, Jin-Zhi
    Wang, Jun
    BIOMATERIALS SCIENCE, 2021, 9 (07) : 2508 - 2518
  • [43] Inhibition of osteopontin modulates tumor-stimulated immune response and suppresses mesothelioma progression
    Psallidas, Ioannis
    Magkouta, Sophia
    Pappas, Apostolos
    Moschos, Charalampos
    Vazakidou, Maria-Eleni
    Roussos, Charis
    Stathopoulos, Georgios
    Kalomenidis, Ioannis
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [44] Tumor lysis syndrome after treatment with sorafenib for hepatocellular carcinoma
    Kudo, Chieko
    Miura, Masahito
    Gamoh, Makio
    Niitani, Tomohito
    Tamagawa, Hiroki
    Takahashi, Kiichi
    Ichikawa, Sonoko
    Sugiyama, Katsuo
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2015, 4 (03): : 147 - 150
  • [45] Tumor lysis syndrome after treatment with sorafenib for hepatocellular carcinoma
    Chieko Kudo
    Masahito Miura
    Makio Gamoh
    Tomohito Niitani
    Hiroki Tamagawa
    Kiichi Takahashi
    Sonoko Ichikawa
    Katsuo Sugiyama
    International Cancer Conference Journal, 2015, 4 (3) : 147 - 150
  • [46] Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma
    Miyahara, Koji
    Nouso, Kazuhiro
    Morimoto, Yuki
    Takeuchi, Yasuto
    Hagihara, Hiroaki
    Kuwaki, Kenji
    Onishi, Hideki
    Ikeda, Fusao
    Miyake, Yasuhiro
    Nakamura, Shinichiro
    Shiraha, Hidenori
    Takaki, Akinobu
    Iwadou, Shouta
    Kobayashi, Yoshiyuki
    Takaguchi, Koichi
    Takuma, Yoshitaka
    Takabatake, Hiroyuki
    Sakaguchi, Kohsaku
    Yamamoto, Kazuhide
    HEPATOLOGY RESEARCH, 2014, 44 (03) : 296 - 301
  • [47] Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation
    Yan, Yuke
    Wang, Liang
    He, Jingjing
    Liu, Pengcheng
    Lv, Xi
    Zhang, Yawu
    Xu, Xiaodong
    Zhang, Lingyi
    Zhang, Youcheng
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 88 : 395 - 402
  • [48] Combination Intensity-Modulated Radiotherapy and Sorafenib Improves Outcomes in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
    Abulimiti, Munire
    Li, Zhenyu
    Wang, Haifeng
    Apiziaji, Palida
    Abulimiti, Yisikandaer
    Tan, Yao
    JOURNAL OF ONCOLOGY, 2021, 2021
  • [49] Sorafenib Suppresses Postsurgical Recurrence and Metastasis of Hepatocellular Carcinoma in an Orthotopic Mouse Model
    Feng, Yu-Xiong
    Wang, Tao
    Deng, Yue-Zhen
    Yang, Pengyuan
    Li, Jing-Jing
    Guan, Dong-Xian
    Yao, Fan
    Zhu, Yin-Qiu
    Qin, Ying
    Wang, Hui
    Li, Nan
    Wu, Meng-Chao
    Wang, Hong-Yang
    Wang, Xiao-Fan
    Cheng, Shu-Qun
    Xie, Dong
    HEPATOLOGY, 2011, 53 (02) : 483 - 492
  • [50] MARK1 suppress malignant progression of hepatocellular carcinoma and improves sorafenib resistance through negatively regulating POTEE
    Lu, Xin
    Chen, Zhiyuan
    Mi, Wenting
    Zheng, Jianming
    Liu, Yubin
    OPEN MEDICINE, 2024, 19 (01):
12345